Naseem Kerr

2.3k total citations · 1 hit paper
8 papers, 782 citations indexed

About

Naseem Kerr is a scholar working on Oncology, Genetics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Naseem Kerr has authored 8 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Genetics and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Naseem Kerr's work include CAR-T cell therapy research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Clinical practice guidelines implementation (1 paper). Naseem Kerr is often cited by papers focused on CAR-T cell therapy research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Clinical practice guidelines implementation (1 paper). Naseem Kerr collaborates with scholars based in United Kingdom and United States. Naseem Kerr's co-authors include D Veale, Adrian L. Harris, G J Gibson, Bruce L. Levine, Simon F. Lacey, Marcela V. Maus, Carl H. June, Brendan M. Weiss, Zhaohui Zheng and Yolanda D. Mahnke and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Naseem Kerr

8 papers receiving 766 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Marcela V. Maus et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Naseem Kerr

Since Specialization

Citations

This map shows the geographic impact of Naseem Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naseem Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naseem Kerr more than expected).

Fields of papers citing papers by Naseem Kerr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naseem Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naseem Kerr. The network helps show where Naseem Kerr may publish in the future.

Co-authorship network of co-authors of Naseem Kerr

This figure shows the co-authorship network connecting the top 25 collaborators of Naseem Kerr. A scholar is included among the top collaborators of Naseem Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naseem Kerr. Naseem Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma breakdown → 2015 ·New England Journal of Medicine ·Alfred L. Garfall, Marcela V. Maus, Wei‐Ting Hwang, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem Kerr, Adam Bagg, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer	434
2	Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers 2015 ·Cancer Research ·János L. Tanyi, Andrew R. Haas, Gregory L. Beatty, Mark A. Morgan, Caitlin Stashwick, Mark H. O’Hara, David L. Porter, Marcela V. Maus, Bruce L. Levine, Simon F. Lacey, Anne Marie Nelson, (unknown), Naseem Kerr, Gabriela Plesa, Carl H. June	17
3	Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. 2015 ·Journal of Clinical Oncology ·Alfred L. Garfall, Marcela V. Maus, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem Kerr, Wei‐Ting Hwang, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer	8
4	Preliminary Evaluation of the Health Background Questionnaire for Pain and Clinical Encounter Form for Pain 2005 ·Pain Medicine ·Jana Mossey, Naseem Kerr, (unknown), Rollin M. Gallagher	2
5	The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival 1993 ·British Journal of Cancer ·D Veale, Naseem Kerr, G J Gibson, (unknown), Adrian L. Harris	200
6	Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer 1989 ·Lung Cancer ·D Veale, Naseem Kerr, G J Gibson, Adrian L. Harris	91
7	Phase 1 study of high-dose hydroxyurea in lung cancer 1988 ·Cancer Chemotherapy and Pharmacology ·D Veale, B.M.J. Cantwell, Naseem Kerr, (unknown), Adrian L. Harris	29
8	First annual meeting of the Association of Cancer Physicians (in conjunction with the 27th AGM of the British Association for Cancer Research). March 24-25, 1986, Bristol, UK. Abstracts 1986 ·British Journal of Cancer ·D Veale, B.M.J. Cantwell, Naseem Kerr, (unknown), (unknown), Adrian L. Harris, Mark Slevin, P. Clark, MA Richards, Richard H. Osborne, S. Malik, Christopher S. Wood, V. Harvey, (unknown), J. S. Malpas, P. F. M. Wrigley	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact